[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Persistent Pulmonary Hypertension of the Newborn- Pipeline Insight, 2019

October 2019 | 60 pages | ID: P1462F3CACD6EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Persistent Pulmonary Hypertension of the Newborn- Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Persistent Pulmonary Hypertension of the Newborn pipeline landscape is provided which includes the disease overview and Persistent Pulmonary Hypertension of the Newborn treatment guidelines. The assessment part of the report embraces, in depth Persistent Pulmonary Hypertension of the Newborn commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Persistent Pulmonary Hypertension of the Newborn collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Persistent Pulmonary Hypertension of the Newborn Understanding

Persistent Pulmonary Hypertension of the Newborn (PPHN) is a syndrome characterized by sustained elevation of pulmonary vascular resistance (PVR) and is often associated with normal or low systemic vascular resistance (SVR). This leads to extrapulmonary shunting from right to left across persistent fetal channels leading to labile hypoxemia. This disorder was previously referred to as persistent fetal circulation (PFC) and is often caused due to the failure of the pulmonary circulation to undergo into the normal transition after birth. The disease is mostly seen in term, and near term infants, it can be seen in some premature infants as well with the respiratory distress or bronchopulmonary dysplasia. Signs and Symptoms of PPHN include rapid breathing, grunting or moaning while breathing, blue color of the lips or around the mouth that gets worse in the first 24 h of life, pale or blotchy color, cold or blue hands and feet, low-blood oxygen levels even after giving oxygen, low-blood pressure, decreased urine output, swelling, etc.

Persistent Pulmonary Hypertension of the Newborn Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Persistent Pulmonary Hypertension of the Newborn targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Persistent Pulmonary Hypertension of the Newborn pipeline report covers 2+ companies. Some of the key players include United Therapeutics Corporation (Treprostinil) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Persistent Pulmonary Hypertension of the Newborn Analytical Perspective by DelveInsight
  • In-depth Persistent Pulmonary Hypertension of the Newborn Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Persistent Pulmonary Hypertension of the Newborn Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Persistent Pulmonary Hypertension of the Newborn report provides an overview of therapeutic pipeline activity for Persistent Pulmonary Hypertension of the Newborn across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Persistent Pulmonary Hypertension of the Newborn therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Persistent Pulmonary Hypertension of the Newborn Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Persistent Pulmonary Hypertension of the Newborn
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Persistent Pulmonary Hypertension of the Newborn to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Persistent Pulmonary Hypertension of the Newborn R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Persistent Pulmonary Hypertension of the Newborn in licensing and out licensing strategies by identifying prospective partners with progressing projects for Persistent Pulmonary Hypertension of the Newborn to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN

2.1. Persistent Pulmonary Hypertension of the Newborn Disease Overview
2.2. Persistent Pulmonary Hypertension of the Newborn History
2.3. Persistent Pulmonary Hypertension of the Newborn Symptoms
2.4. Persistent Pulmonary Hypertension of the Newborn Causes
2.5. Persistent Pulmonary Hypertension of the Newborn Pathophysiology
2.6. Persistent Pulmonary Hypertension of the Newborn Diagnosis
  2.6.1. Diagnostic Guidelines

3. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Persistent Pulmonary Hypertension of the Newborn companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Persistent Pulmonary Hypertension of the Newborn Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Persistent Pulmonary Hypertension of the Newborn Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. United Therapeutics Corporation (Treprostinil)
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN KEY COMPANIES

8.1. United Therapeutics Corporation
8.2. Mallinckrodt

9. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN KEY PRODUCTS

9.1. Treprostinil
9.2. Nitric oxide

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN- UNMET NEEDS

12. PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Persistent Pulmonary Hypertension of the Newborn Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Persistent Pulmonary Hypertension of the Newborn companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Persistent Pulmonary Hypertension of the Newborn Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

United Therapeutics Corporation
Mallinckrodt
Proteo Biotech
Beyond Air
Farmacon-IL
Merck Sharp & Dohme


More Publications